We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Stock Moves -1.9%: What You Should Know
Read MoreHide Full Article
Illumina (ILMN - Free Report) closed the most recent trading day at $273, moving -1.9% from the previous trading session. This move was narrower than the S&P 500's daily loss of 2.81%. Elsewhere, the Dow lost 2.94%, while the tech-heavy Nasdaq lost 3%.
Heading into today, shares of the genetic testing tools company had lost 5.16% over the past month, lagging the Medical sector's loss of 1.87% and the S&P 500's loss of 3.97% in that time.
Investors will be hoping for strength from ILMN as it approaches its next earnings release. The company is expected to report EPS of $1.24, down 22.5% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $854.06 million, up 0.95% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.86 per share and revenue of $3.89 billion, which would represent changes of +4.41% and +9.74%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ILMN is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, ILMN is currently trading at a Forward P/E ratio of 40.57. Its industry sports an average Forward P/E of 33.44, so we one might conclude that ILMN is trading at a premium comparatively.
We can also see that ILMN currently has a PEG ratio of 2.63. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ILMN's industry had an average PEG ratio of 1.78 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Illumina (ILMN) Stock Moves -1.9%: What You Should Know
Illumina (ILMN - Free Report) closed the most recent trading day at $273, moving -1.9% from the previous trading session. This move was narrower than the S&P 500's daily loss of 2.81%. Elsewhere, the Dow lost 2.94%, while the tech-heavy Nasdaq lost 3%.
Heading into today, shares of the genetic testing tools company had lost 5.16% over the past month, lagging the Medical sector's loss of 1.87% and the S&P 500's loss of 3.97% in that time.
Investors will be hoping for strength from ILMN as it approaches its next earnings release. The company is expected to report EPS of $1.24, down 22.5% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $854.06 million, up 0.95% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.86 per share and revenue of $3.89 billion, which would represent changes of +4.41% and +9.74%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ILMN is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, ILMN is currently trading at a Forward P/E ratio of 40.57. Its industry sports an average Forward P/E of 33.44, so we one might conclude that ILMN is trading at a premium comparatively.
We can also see that ILMN currently has a PEG ratio of 2.63. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ILMN's industry had an average PEG ratio of 1.78 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 102, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.